" Instead, #Hepatoblastoma #tumors contain a large suppressive #myeloid compartment which poses opportunities for targeting. Specifically, therapeutic antibodies
targeting the #tumor antigen #GPC3 to induce ADCP by #macrophages, in combination with myeloid
#ImmuneCheckpointBlockade (#CD47/SIRPa, or VISTA) could be a feasible strategy to explore in future studies"
Krijgsman et al. from Vercoulen lab in the #UMCUtrecht, on #bioRXiv:
https://www.biorxiv.org/content/10.1101/2023.06.28.546852v1
Check out some #CoolScienceImages from a Nature Communications study on #fluorescencefriday. Nikolos et al. showed that an iDAMP blockade approach synergizes with #chemotherapy and sensitizes #bladdercancer to #immunotherapy in #preclinicalmodels.
https://www.nature.com/articles/s41467-022-29026-9
Music: Baby Don’t Hurt Me by David Guerra, Anne-Marie, & Coi Leray
#CancerMoonshot
#CancerMoonshotSeminar
#CMSSChan
#cancerresearch
#ImmuneCheckpointBlockade
Chemoimmunotherapy recently failed to improve objective response for patients with advanced muscle-invasive bladder cancer (MIBC). Here using two murine models of immune-excluded MIBC, the authors show that resistance to chemoimmunotherapy can be overcome by blocking the COX-2/prostaglandin E2 axis, reinvigorating anti-tumor immune responses.
Cool paper dissecting the mechanism of action of #immunecheckpointblockade, anti-CTLA-4, and showing the important role of #myeloidcells #macrophages
"Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling"
#naturecancer #immunotherapy #immunecheckpointinhibitor #macrophages #IFNI
Yofe et al. demonstrate that FcγR engagement early after anti-CTLA-4 blockade induces a rapid remodeling of innate immunity and activation of type I interferon signaling, which are crucial for successful anti-CTLA-4 therapy.
#Senescence #ImmuneSurveillance
Next-gen #Senolytic
#ImmuneCheckpointBlockade activates CD8+ T cytotoxicity against (inflammed🔥) PD-L1+ senescent cells->
⏬adverse phenotypes in🐭#Aging+#NASH
Dr. Yoshikazu Johmura & Makoto Nakanishi labs Nature 2022
https://www.nature.com/articles/s41586-022-05388-4
Arjan Boltjes
Claire McCarthy
Judit Svensson Arvelund
Hao Yin